A number of clinical trials with ZD4054 Ongoing studies are currently in progress.
More studies will be added in due course. Additional ZD4054 Ongoing study information is available on ClinicalTrials.gov. | Study Number | Study Phase | Start Date | Recruitment Status | | D4320C00006 | Phase II | Aug-2004 | Active, not recruiting | | A phase II, randomised, double-blind, parallel-group, placebo-controlled, multi-centre study to assess the efficacy and safety of once-daily orally administered ZD4054 15 mg and 10 mg doses in pain-free or mildly symptomatic patients with prostate cancer and bone metastases, who have rising serum prostate specific antigen (PSA) levels despite medical or surgical castration | | D4320C00010 | Phase I | 2-Jul-2008 | Active, not recruiting | | A Randomised, Open-label, Crossover, Phase I Study to Assess the Effect of Multiple Oral Doses of ZD4054 on the Pharmacokinetics of a CYP450 3A Probe (midazolam) in Healthy Male Subjects | | D4320C00014 | Phase III | 10-Nov-2007 | Recruiting | | A Phase III Trial to test the efficacy of ZD4054, an Endothelin A Receptor Antagonist, versus Placebo in Patients with Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who are Pain Free and Mildly Symptomatic. | | D4320C00015 | Phase III | 15-Jan-2008 | Recruiting | | A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients. | | D4320C00017 | Phase I | 30 Jun 2008 | Recruiting | | A Phase I, Double-blind, Double-dummy, Placebo-controlled, Randomised, Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Volunteers Aged 18 to 45 Years. | | D4320C00020 | Phase I | 28-Mar-2006 | Active, not recruiting | | A Phase I Study of ZD4054 in Combination With Docetaxel in 2 Parts, an Open-Label, Non-Randomized, Dose-Finding Part and a Double-Blind, Placebo-Controlled, Randomized Dose Expansion Part, in Patients With Metastatic Hormone-Refractory Prostate Cancer. | | D4320C00025 | Phase II | 17 Apr 2008 | Recruiting | | An Open-label Comparative Study of the Pharmacokinetics, Safety and Tolerability of ZD4054 following a 10 mg Single Oral Dose of ZD4054 to Healthy Subjects and to Subjects with Mild, Moderate and Severe Hepatic Impairment | | D4320C00028 | Phase I | 24-Jun-2008 | Active, not recruiting | | A Randomised, Open-label, Single-centre, Crossover Study in Healthy Male Volunteers to Assess the Effect of Food on the Pharmacokinetics of a 10 mg Single Oral Dose of ZD4054. | | D4320C00029 | Phase I | 19 Jun 2008 | Completed | | A Phase I, Randomised, Single-blind, Single-centre, Incomplete-block Crossover, Relative Bioavailability Study in Healthy Male Subjects for ZD4054 Immediate Release Tablets | | D4320C00033 | Phase III | 15 Jan 2008 | Recruiting | | A Phase III, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-Resistant Prostate Cancer. | | D4320C00035 | Phase II | 12 Aug 2008 | Recruiting | | A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination with Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients with Non-small Cell Lung Cancer who Have Failed One Prior Platinum-based Chemotherapy Regimen | | 4054IL/0004 | Phase II | | Active, not recruiting | | A Phase IIa. Open-Label, Multicenter, Dose-Escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 Given Orally Once Daily in Subjects with Metastatic Prostate Cancer |
|